Clinical outcome after trimipramine in patients with delusional depression - A pilot study

Pharmacopsychiatry

Volumn 36, Issue 1, 2003, Pages 12-17

  Frieboes, R M ^a   Sonntag, A ^a   Yassouridis, A ^a   Eap, C B ^b   Baumann, P ^b   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; NORTRIMIPRAMINE; TRIMIPRAMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSIONAL DISORDER; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOPHARMACOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOMETRICS; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME; TRIMIPRAMINE;

EID: 0037244469     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38087     Document Type: Article

References (33)

1. Bender S, Olbrich H, Hornstein C, Schöne W, Falkai P. Antipsychotic efficacy of the antidepressant trimipramine: double-blind comparison with the phenothiazine perazine. Biol Psychiatry 1997; 42: 231S
2. Berger M, Gastpar M. Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci 1996; 246: 235-239
3. Chan CH, Janicak PG. Davis JM, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiat 1987; 48: 197-200
4. Coryell W. The treatment of psychotic depression. J Clin Psychiat 1998; 59 (Suppl. 1): 22-29
5. Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K et al. Steady-state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-214
6. Eap CB, Koeb L, Holsboer-Trachsler E, Baumann P. Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. Ther Drug Monit 1992; 14: 380-385
7. Gross G, Xin X, Gastpar M. Trimipramine - Pharmacological reevaluation and comparison with clozapine. Neuropharmacology 1991; 30: 1159-1166
8. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960; 23: 56-62
9. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course. J Psychiatr Res 1994; 28: 381-399
10. th Generation of Progress. New York: Raven Press, 1995: p. 957-970
11. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999; 33: 181-214
12. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
13. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996; 17: 187-205
14. Laakmann G. Psychopharmakoendokrinologie und Depressionsforschung. Monographien aus dem Gesamtgebiete der Psychiatrie. 46: Berlin, Heidelberg, New York: Springer
15. Modell S, Lauder CJ, Schreiber W, Huber J, Krieg JC, Holsboer F. Hormonal response pattern in the combinded Dex-CRH test is stable over time in subjects at high familial risk for affective disorder. Neuropsychopharmacology 1998; 18: 253-262
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
17. Overall JE, Gotham DR. Brief Psychiatric Rating Scale. In Guy W (eds.). ECDEU assessment manual for psychopharmacology, revised. Rockville, Maryland, USA: National Institute of Mental Health, 1976
18. Perry PJ, Zeilmann C, Armdt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-240
19. Posener JA, DeBattista C, Williams GH, Kraemer HC, Kalezhan M, Schatzberg AF. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 2000; 57: 755-760
20. Reul JM, Labeur MS, Grigoriadis DE, De Souza EB, Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994; 60: 509-519
21. Reul JM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993; 133: 312-320
22. Rothshild AJ, Langlais PJ, Schatzberg AF, Walsh FX, Cole JO, Bird ED. Dexamethasone increases plasma free dopamine in man. J Psychiatr Res 1984; 18: 217-223
23. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiat 1993; 54: 338-342
24. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzbert AF. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biol Psychiatry 1993; 34: 392-400
25. Rudorfer MV, Hwu HG, Clayton PJ. Dexamethasone suppression test in primary depression: significance of family history and psychosis. Biol Psychiatry 1982; 17: 41-48
26. Schatzberg AF, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res 1985; 19: 57-64
27. Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 1996; 4: 1-13
28. Spiker DG, Kupfer DJ. Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord 1988; 14: 21-23
29. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430-436
30. Steiger A, Benkert O, Wöhrmann S, Steinseifer D, Holsboer F. Effects of trimipramine on sleep EEG, penile tumescence and nocturnal hormonal secretion. A long-term study in 3 normal controls. Neuropsychobiology 1989; 21: 71-75
31. Steiger A, von Bardeleben U, Guldner J, Lauer C, Rothe B, Holsboer F. The sleep EEG and nocturnal hormonal secretion. Studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 125-137
32. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996; 153: 1631-1633
33. Von Zerssen D. Self-rating scales for evaluation of patient's subjective state in cross-sectional and longitudinal studies of psychopathology. Arch Psychiatr Nervenkr 1973; 217: 299-314